GLP-1RAs, including semaglutide and liraglutide, are frequently used today for the treatment of type 2 diabetes and obesity. A recent study investigated whether and how overweight and/or diabetic psoriasis patients benefit from treatment with GLP-1RAs. Initial results were presented at this year’s congress of the European Academy of Dermatology and Venereology (EADV).
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- Plastic surgery and reconstructive microsurgery for DFS
Functional limb preservation between infection control, vascular medicine and resurfacing
- Adrenogenital syndrome
Clinical care from birth to adulthood
- New approvals, current study data and ADC development
Antibody-drug conjugates in gynecologic oncology
- From symptom to diagnosis
Pneumology – Covid-19: a review
- Abdominal aortic aneurysms in primary care
Risk-stratified screening and prophylaxis
- Cardiology
Minimally invasive – the quiet triumph of modern heart surgery
- Age-related neurocognitive disorders